首页 印度格列卫价格 新版(The price of new India Gleevec)

印度格列卫价格 新版(The price of new India Gleevec)

举报
开通vip

印度格列卫价格 新版(The price of new India Gleevec)印度格列卫价格 新版(The price of new India Gleevec) 印度格列卫价格 新版(The price of new India Gleevec) Generic name: imatinib mesylate (produced by NATCO, India) is called VEENAT. Commonly known as: India Gleevec) Name: VEENAT English Name: Imatinib Mesylate Capsules specifi...

印度格列卫价格 新版(The price of new India Gleevec)
印度格列卫价格 新版(The price of new India Gleevec) 印度格列卫价格 新版(The price of new India Gleevec) Generic name: imatinib mesylate (produced by NATCO, India) is called VEENAT. Commonly known as: India Gleevec) Name: VEENAT English Name: Imatinib Mesylate Capsules specifications: 120 bottle / Pinyin: Jiahuangsuan Yimatini Jiaonang VEENAT for India NATCO company, received FDA approval, not in Chinese, so in China for illegal drugs, the only function of Encyclopedia notes. The following is the introduction of Gleevec introduction, VEENAT is not introduced, India is commonly known as the unsuspecting gleevec. [1] Greve (imatinib mesylate) is a new generation of targeted anticancer drugs that inhibit the platelet derived growth factor (PDGF) receptor protein kinase. Greve is one of the most effective of all antineoplastic drugs. Greve was effective in the treatment of newly diagnosed chronic myelogenous leukemia (CML) by more than 94%, and 76% of patients received cytological remission. Greve (imatinib mesylate) packed 120 tablets per bottle, each containing 119.45 mg imatinib mesylate, equivalent to 100mg imatinib free base. Medicine in white polyethylene bottles. The results show that the phase three clinical trial of Gleevec on newly diagnosed chronic myelogenous leukemia (CML) treatment efficiency more than 94%, and 76% of the patients can be relieved of the cytological effective rate, accelerated phase and blast crisis also reached 71% and 31% respectively. The effective rate of Greve on gastrointestinal stromal tumors is as high as 67%. Indication: Greve (imatinib mesylate) is used to treat newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in adults in chronic phase. Greve (imatinib mesylate) for the treatment of Philadelphia chromosome positive in blastic phase and accelerated phase chronic myelogenous leukemia, imatinib mesylate for the treatment of interferon has also treated in the chronic phase of chronic myelogenous leukemia. Greve (imatinib mesylate) is also used to treat relapsed bone marrow failure or chronic myelogenous leukemia in children who are not treated with interferon. Gastrointestinal stromal tumors (GIST) Greve (imatinib mesylate) is used for the treatment of KIT (CD117) - positive inoperable or metastatic malignant gastrointestinal stromal tumors! The most common toxic side effects include superficial edema, malignant and vomiting, muscle soreness, muscle spasm, skin rashes and diarrhea. Blood toxicity, including neutropenia and thrombocytopenia is Gleevec (imatinib) common side effects of treatment, but they occur in newly diagnosed CML patients in low. 2 character editor Imatinib mesylate, the chemical name is 4-[(4- methyl -1- methyl piperazine)]-N-[4- methyl -3-[[4- (3- pyridyl) -2-] amino] phenyl pyrimidine - aniline methyl sulfonate, the molecular formula is C29H31N7O CH4SO3, a molecular weight of 589.7. The content of this capsule is white to white powder. Imatinib is a small molecule kinase inhibitor. Imatinib film coated tablets containing the same amount of imatinib mesylate, imatinib dose 100 mg and 400 mg two. Its structural formula is: 3 feature therapy editor Gleevec, food and Drug Administration approved indications for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase, accelerated phase or blast crisis. Philadelphia - for the treatment of chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase, accelerated phase or blast phase [1]; For the treatment of unresectable and / or metastatic malignant gastrointestinal stromal tumor (GIST) in adult patients; for adapting to the information safety and effectiveness in the main research materials from abroad, China people limited data: - for the treatment of adults with relapsed or refractory acute lymphoblastic leukemia in Philadelphia with positive (body color Ph+ ALL). - for the treatment of adult patients with eosinophilia syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR alpha fusion kinase. Imatinib mesylate is the world's first approved tumor associated signaling inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumors. Initially, treatment should be performed by a physician who has a treatment experience for cml. The blast phase and accelerated phase patients imatinib mesylate, the recommended dose of 600mg/ day, the failure of interferon therapy in chronic phase 400mg/ patients, all of which were taken orally once daily, appropriate medication during meals, and drink a glass of water, as long as the effective, it should continue to take. If the blood picture permits no serious adverse drug reactions, the dosage may be increased from 400mg/ days to 600mg/ days, or from 600mg/ days to 800mg/ days (400mg, orally) 4 usage editor The initial dose of chronic myelogenous leukemia and accelerated phase patients, Imatinib mesylate, the recommended dose is 600 mg/; the failure of interferon therapy in chronic phase patients, and resection or metastasis of inoperable malignant gastrointestinal stromal tumor (GIST) patients, the recommended dose is 400 mg/, all of which were taken orally 1 times a day, appropriate medication during meals, and drink a large glass of water, as long as the effective, it should continue to take. If blood permits, no serious adverse reactions of drugs, dosage can be increased from 400 mg/ to 600 mg/ in the following circumstances, or increased from 600 mg/ to 800 mg/ (400 mg, 2 doses): disease progression and treatment for at least 3 months after failing to obtain satisfactory hematologic response, has achieved hematologic response to disappear. We must a DJ DJ简历DJ简历DJ简历DJ简历DJ简历 ust the dose in the following cases: in the treatment of serious non hematologic adverse reactions (such as severe water retention), should be discontinued until the adverse reactions disappeared, then according to the severity of the adverse reaction dose adjustment. To adjust the dose of serious side effects such as liver: bilirubin increased more than 3 times the upper limit of the normal range or transaminase elevated above the normal range 5 times the upper limit, should be discontinued until the above indexes were reduced to the upper limit of the normal range of 1.5 or 2.5 times. Neutropenia or thrombocytopenia adjusted dose reduction: accelerated or blast phase: if there is a serious reduction of neutrophil and platelet neutrophil neutral (less than 0.5 * 109/L and / or platelet is less than 10 * 109/L, the recommended dose is reduced to 400 mg/. If the blood cells decreased continuously for 2 weeks, then further reduced to 300 doses of mg/, such as blood cells decreased continuously for 4 weeks, should be discontinued until neutrophil and platelet over 1 * 109/L = 20 * 109/L. The reused dose was 300 mg/ days. Interferon alpha treatment failure in patients with chronic phase: when neutrophils less than 1 * 109/L and / or platelet is less than 50 * 109/L should be stopped, only in neutrophils and platelets over 1.5 * 109/L = 75 * 109/L to restore the medication, dosage of 400 mg/, such as neutrophil or platelet to reduce to the value, to restore the medication dose was reduced to 300 mg/. In patients with liver failure: liver damage dose of imatinib mesylate plasma concentration can be increased, so the patients with this medicine should be cautious, there is no damage of liver function in patients with imatinib mesylate, clinical data, to put forward proposals to adjust dosage. Renal failure in elderly patients and the dose: known creatinine clearance rate can decrease with age, and the age of imatinib mesylate pharmacokinetics has no obvious effect, because in patients with impaired renal function has not yet been tested in clinical trials, it is impossible to make dose adjustment proposals. 5 side effects, methods of editing Usually patients Greve (imatinib mesylate)) produce adverse reactions with other treatment modalities (such as chemotherapy) compared to the adverse reaction, is much smaller, but as long as the symptomatic treatment, after a period of time, most patients can tolerate. In the event of adverse reactions, the correct method is to listen to the doctor's advice and adjust the treatment according to the doctor's instructions so as to effectively manage these adverse reactions and achieve the best effect. Preventing side effects: as long as the use of Gleevec side effects that may arise in advance of targeted prevention. Not only can the patient enhance the confidence of the cure, but also can avoid unnecessary symptoms, so that money suffered losses. India is the effect of Gleevec for liver and kidney, while taking Gleevec can focus on these two areas of maintenance. The liver can take gantaile such medicine to protect liver, usually eat some good food on the liver, there are also some traditional Chinese medicine ingredients containing Yanggan porridge. The kidney has not been very effective in retaining kidney drugs, and eating more diuretic foods, such as wax gourd. At the same time, we should drink plenty of water, drink plenty of water, can supplement body fluids, enhance blood circulation, promote metabolism, drink plenty of water, but also conducive to digestion, absorption and elimination of waste, reduce metabolites and toxins on the liver damage. Once again need a balanced diet rich in protein, carbohydrates, fats, vitamins and minerals to keep the corresponding proportion; while maintaining five taste unbiased; try to eat less spicy food, eat more fresh vegetables and fruits; not overeating or hunger and satiety unevenness. Clinical proof, mood is comfortable, the cure to the patient also is very helpful. The way of preventing side effects for the above is used when gleevec. So what are the main adverse reaction of Gleevec? How should we deal with adverse reactions? Greve's side effects are generally mild to moderate, and usually disappear after one or two months of treatment. If the patient is unable to tolerate or respond to a more intense situation, the patient's physician should be advised to reduce or suspend treatment. The chief adverse effects of Greve: Bone marrow suppression Gastrointestinal Response Musculoskeletal toxicity Liver toxicity Edema Skin rash Itching If any of these adverse events occur, please inform your doctor immediately so that these adverse events can be treated in a timely manner so that you can benefit better from the treatment of Gleevec (imatinib mesylate). Bone marrow suppression: myelosuppression is a therapeutic response. Prior to treatment, many Ph+ cells are present in the patient, and these Ph+ cells play a major role in hematopoiesis. When patients received Greve (imatinib mesylate) treatment, the elimination of Ph+ cells, resulting in inhibition of hematopoietic function of patients. This is actually a positive therapeutic effect of Gleevec (imatinib mesylate). You do not have to worry, the doctor will be in accordance with your specific circumstances, to take appropriate measures to solve. Only in the blood cells decreased to a certain extent when they need to stop Gleevec (imatinib mesylate)) treatment: Stop when necessary: Gleevec (imatinib mesylate)) treatment - adjusted dose (Greve (imatinib mesylate) dose per day is not less than 300mg) - support treatment, including supplements, water, etc. Gastrointestinal reactions including nausea, vomiting, and diarrhea. Countermeasures include: - take it with the food and take a large glass of water Take at least 2 hours before going to bed - divide the dose of 400 mg into 200 mg 2 times a day In a severe reaction in patients with antiemetics and antidiarrheal drugs, such as domperidone and Norfloxacin - proton pump inhibitors, such as omeprazole - antacids, such as ranitidine - antihistamines, such as cetirizine, are musculoskeletal toxicity including muscle cramps, arthralgia and bone pain - supplement calcium, such as calcium gluconate - Taking nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin Edema: - mild (often orbital): restriction of salt intake and / or the use of diuretics, such as hydrochlorothiazide - severe (pulmonary edema, pleural / pericardial effusion, ascites): use a diuretic, reduce or stop treatment, and measure body weight regularly Rash: rash, usually mild, papules most often occurring in arms and trunk, and may be given antihistamines, topical or oral steroids - exfoliative rash is extremely rare and serious, should stop Gleevec (imatinib mesylate)) treatment, and received systemic steroids
本文档为【印度格列卫价格 新版(The price of new India Gleevec)】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
下载需要: 免费 已有0 人下载
最新资料
资料动态
专题动态
is_196623
暂无简介~
格式:doc
大小:36KB
软件:Word
页数:10
分类:生活休闲
上传时间:2018-02-04
浏览量:57